We work closely with our pharmaceutical/academic partners to unlock new possibilities for drug delivery and therapeutic impact. Our patented Carbon Nanoparticle (CNP) technology offers a adaptive platform for encapsulating and delivering therapeutic agents, allowing us to overcome critical barriers, such as crossing the blood-brain barrier (BBB) and reducing toxicity.
Our partnership process is designed to ensure the seamless integration of our technology with your therapeutic goals. From initial screening to clinical readiness, we support each stage of development with scientific rigor and attention to scalability:
Initial Screen: We begin with a detailed evaluation of your molecule(s) for encapsulation feasibility, tunability with our CNP technology, and controlled release studies in vitro. This step establishes the foundation for achieving the desired therapeutic impact and controlled delivery.
Development and Validation: For promising candidates, we progress to in vivo studies, including pharmacokinetics (PK), pre-clinical efficacy, and combination therapy evaluations. These studies are designed to demonstrate how our technology can enhance bioavailability, prolong half-life, and improve therapeutic targeting.
Process Scalability: We prioritize scalability and ensure that each formulation is optimized for efficient, large-scale manufacturing to support your commercial goals. Our team collaborates with you to refine processes that maintain quality, consistency, and cost-effectiveness as we prepare for regulatory approval and market readiness.
Through a collaborative approach, we empower our partners to push the boundaries of therapeutic potential. Discover how our CNP platform can amplify the effectiveness of your therapies and open new pathways for innovative treatments in areas of high unmet need.
Driving Innovation with Our Trusted Technology Partners
Accelerating the future with visionary partners and innovative solutions.
